Impact and costs of a hepatitis C virus screening programme for adults hospitalised at an academic medical centre

BMJ Open Quality

article

Timothy J Whitman¹  Cindy D Noyes¹  Andrew J Hale¹  Devika Singh¹  Stephen G DeVoe²  Allen B Repp²  Kristen K Pierce¹  Louis B Polish¹  Beth D Kirkpatrick¹  Jean Dejace¹  Lindsay M Smith¹  Tim Lahey¹  Christopher D Huston¹  Laura J Catoe¹  Prateek Ghatage¹  Sean Bullis¹  W Kemper Alston¹ 

[1] Division of Infectious Diseases, Department of Medicine , The Robert Larner, MD College of Medicine at the University of Vermont;Department of Medicine Quality Program , The Robert Larner, MD College of Medicine at the University of Vermont

关键词: standards of care;    quality improvement;    cost-effectiveness;    clinical practice guidelines;   

DOI  :  10.1136/bmjoq-2020-001248

学科分类：药学

来源: BMJ Publishing Group

【 摘 要 】

Approximately 1.7% of the US populationhas chronic hepatitis C virus (HCV) infection, but among adults born between 1945and 1965 prevalence increases to 3.25%, andthis birth cohort accounts for almost 75% ofthe total burden of HCV.1 2 The availabilityof effective direct-acting antiviral (DAA)therapy for HCV makes screening, linkageto care and treatment a national priority.The Centers for Disease Control and Prevention (CDC) and US Preventative ServicesTask Force (USPSTF) have recommendedone-time HCV screening for persons bornbetween 1945 and 1965,2 3 yet only 14%–17%of this cohort has been screened for HCV.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND